Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $78
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Edward Nash maintains a Buy rating on Corcept Therapeutics (NASDAQ:CORT) and raises the price target from $38 to $78.
July 31, 2024 | 12:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity analyst Edward Nash maintains a Buy rating on Corcept Therapeutics and significantly raises the price target from $38 to $78.
The significant increase in the price target from $38 to $78 by a reputable analyst suggests strong confidence in Corcept Therapeutics' future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100